cRGD-Functionalized Silk Fibroin Nanoparticles: A Strategy for Cancer Treatment with a Potent Unselective Naphthalene Diimide Derivative.

NDI RGD active targeting anticancer brain tumours cyclic pentapeptides drug delivery integrin antagonist naphthalene diimides silk fibroin nanoparticles

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Mar 2023
Historique:
received: 24 12 2022
revised: 03 02 2023
accepted: 07 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Developing drug delivery systems to target cytotoxic drugs directly into tumor cells is still a compelling need with regard to reducing side effects and improving the efficacy of cancer chemotherapy. In this work, silk fibroin nanoparticles (SFNs) have been designed to load a previously described cytotoxic compound (NDI-1) that disrupts the cell cycle by specifically interacting with non-canonical secondary structures of DNA. SFNs were then functionalized on their surface with cyclic pentapeptides incorporating the Arg-Gly-Asp sequence (

Identifiants

pubmed: 36980611
pii: cancers15061725
doi: 10.3390/cancers15061725
pmc: PMC10046852
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Ministry of Health
ID : MINSAL_INVITRO_TUMOR, CUP E85F21003590001
Organisme : nterreg V-A Italy-Switzerland 2014-2020, ATEx-Advanced Therapies Experiences
ID : Project ID 3859153

Références

Nanoscale Res Lett. 2021 Dec 5;16(1):173
pubmed: 34866166
Mini Rev Med Chem. 2009 Oct;9(12):1439-46
pubmed: 19929817
Bioorg Med Chem. 2012 Nov 1;20(21):6416-22
pubmed: 23021342
J Biol Chem. 2015 Feb 20;290(8):4545-4551
pubmed: 25568317
CA Cancer J Clin. 2022 Mar;72(2):144-164
pubmed: 34751943
Bioorg Med Chem Lett. 2008 Mar 1;18(5):1668-73
pubmed: 18243701
J Med Chem. 2013 Apr 11;56(7):2959-74
pubmed: 23514618
J Drug Target. 2009 Jul;17(6):459-67
pubmed: 19527117
Molecules. 2021 Aug 19;26(16):
pubmed: 34443620
Onco Targets Ther. 2016 May 27;9:3153-62
pubmed: 27313461
J Org Chem. 2017 Oct 20;82(20):11091-11101
pubmed: 28953382
Phys Chem Chem Phys. 2016 Jan 28;18(4):2871-7
pubmed: 26733046
Theranostics. 2011 Feb 17;1:189-200
pubmed: 21547159
Br J Cancer. 1998 Feb;77(4):530-6
pubmed: 9484807
Int J Pharm. 2017 Mar 30;520(1-2):86-97
pubmed: 28163224
Cells. 2019 Nov 13;8(11):
pubmed: 31766310
Int J Mol Sci. 2019 Oct 07;20(19):
pubmed: 31591367
Cardiovasc Res. 2005 Jun 1;66(3):552-61
pubmed: 15914120
J Org Chem. 2019 Dec 6;84(23):15726-15734
pubmed: 31693859
Chemistry. 2019 Aug 22;25(47):11085-11097
pubmed: 31219221
Trends Cell Biol. 2008 Jun;18(6):257-63
pubmed: 18456497
Organogenesis. 2013 Jul-Sep;9(3):143-8
pubmed: 23974173
Cell Death Differ. 2013 Mar;20(3):369-81
pubmed: 23154389
Biomacromolecules. 2011 Sep 12;12(9):3344-9
pubmed: 21790142
ACS Med Chem Lett. 2020 Jul 16;11(8):1634-1644
pubmed: 32832034
Molecules. 2019 Jan 24;24(3):
pubmed: 30682828
ChemMedChem. 2008 Oct;3(10):1589-603
pubmed: 18770516
Cancers (Basel). 2017 Jul 26;9(8):
pubmed: 28933725
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
J Biomed Mater Res A. 2020 Apr;108(4):839-850
pubmed: 31854488
J Control Release. 2014 Sep 28;190:451-64
pubmed: 24794900
Int J Biochem Cell Biol. 2013 May;45(5):1012-5
pubmed: 23428797
ACS Appl Mater Interfaces. 2017 Sep 20;9(37):31600-31611
pubmed: 28836425
J Med Chem. 2004 Sep 23;47(20):4829-37
pubmed: 15369386
Adv Drug Deliv Rev. 2016 Feb 1;97:111-43
pubmed: 26686830
Int J Nanomedicine. 2016 Nov 10;11:5945-5958
pubmed: 27877040
Biomaterials. 2018 Apr;161:306-320
pubmed: 29427926
Cancers (Basel). 2021 Mar 09;13(5):
pubmed: 33803385
Cell Mol Life Sci. 1998 Jun;54(6):502-13
pubmed: 9676570
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17347-52
pubmed: 17954919
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9482-7
pubmed: 12874388
Mol Cancer. 2021 Feb 25;20(1):40
pubmed: 33632214
Biomaterials. 2019 Aug;212:39-54
pubmed: 31103945
Front Oncol. 2021 Sep 30;11:751875
pubmed: 34660316
Int J Biol Macromol. 2003 Dec;33(4-5):203-13
pubmed: 14607365

Auteurs

Valentina Pirota (V)

Department of Chemistry, University of Pavia, Viale Taramelli 10, 27100 Pavia, Italy.

Giovanni Bisbano (G)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.

Massimo Serra (M)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.

Maria Luisa Torre (ML)

Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.
PharmaExceed S.r.l., Piazza Castello, 19, 27100 Pavia, Italy.

Filippo Doria (F)

Department of Chemistry, University of Pavia, Viale Taramelli 10, 27100 Pavia, Italy.

Elia Bari (E)

Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.

Mayra Paolillo (M)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.

Classifications MeSH